Andrew Witty

Latest stories

14h
FOX Business
The Single Most Important Thing About GlaxoSmithKline's Q1 Reportspeak to the most important aspect of GSK's Q1 report: namely that it delivered
The Single Most Important Thing About GlaxoSmithKline's Q1 Report
FOX Business / Posted 14 hours ago
speak to the most important aspect of GSK's Q1 report: namely that it delivered on every single one of the goals CEO Sir Andrew Witty laid out prior to the beginning of fiscal 2016. GSK hit every single one of its targets For starters, Witty... Read more
14h
FOX Business
The Single Most Important Thing About GlaxoSmithKline's Q1 Reportspeak to the most important aspect of GSK's Q1 report: namely that it delivered
The Single Most Important Thing About GlaxoSmithKline's Q1 Report
FOX Business / Posted 14 hours ago
speak to the most important aspect of GSK's Q1 report: namely that it delivered on every single one of the goals CEO Sir Andrew Witty laid out prior to the beginning of fiscal 2016. GSK hit every single one of its targets For starters, Witty... Read more
5d
Bolton News
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Bolton News / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Wandsworth Guardian
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Wandsworth Guardian / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Hampshire Chronicle
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Hampshire Chronicle / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Streatham Guardian
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Streatham Guardian / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
St Albans & Harpenden Review
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
St Albans & Harpenden Review / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Croydon Guardian
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Croydon Guardian / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
heraldscotland
GlaxoSmithKline bolsters profits by nearly one-fiftha series of asset swaps with Swiss rival Novartis. The company is also on the
GlaxoSmithKline bolsters profits by nearly one-fifth
heraldscotland / Posted 5 days ago
a series of asset swaps with Swiss rival Novartis. The company is also on the hunt for a new chief executive after Sir Andrew Witty announced he will retire on March 31 2017, ending more than three decades with the business. He said the first... Read more
5d
This is Oxfordshire
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
This is Oxfordshire / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Lancashire Telegraph
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Lancashire Telegraph / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Northern Echo
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Northern Echo / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
West Moreland Gazette
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
West Moreland Gazette / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Kingston Guardian
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Kingston Guardian / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Oxford Mail
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Oxford Mail / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Bury Times
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Bury Times / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Gazette
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Gazette / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
guardian-series
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
guardian-series / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Greenock Telegraph
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Greenock Telegraph / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Harrow Times
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Harrow Times / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
This is West Country
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
This is West Country / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Gazette News
GlaxoSmithKline profits provide shot in arm for FTSE 100while vaccines climbed 14% to £882 million and consumer healthcare picked up 4%
GlaxoSmithKline profits provide shot in arm for FTSE 100
Gazette News / Posted 5 days ago
while vaccines climbed 14% to £882 million and consumer healthcare picked up 4% to £1.76 billion. Chief executive Sir Andrew Witty said its performance underscored the "momentum" the firm was making thanks to rising sales of new products and... Read more
20 related stories
5d
Channel NewsAsia
GlaxoSmithKline rebound gathering pace, says outgoing CEOcourse to achieve a promised return to growth in 2016. The results help vindic
GlaxoSmithKline rebound gathering pace, says outgoing CEO
Channel NewsAsia / Posted 5 days ago
course to achieve a promised return to growth in 2016. The results help vindicate the claims of outgoing Chief Executive Andrew Witty that the British drugmaker is on the road to recovery, with demand for new respiratory and HIV medicines... Read more
6 related stories
5d
Channel NewsAsia
Higher margins and new drugs help GlaxoSmithKline beat forecaststo achieve a promised return to growth in 2016. The results may help vindicate
Higher margins and new drugs help GlaxoSmithKline beat forecasts
Channel NewsAsia / Posted 5 days ago
to achieve a promised return to growth in 2016. The results may help vindicate the claims of outgoing Chief Executive Andrew Witty that the British drugmaker is on the road to recovery, with demand for new respiratory and HIV medicines... Read more
6 related stories
5d
The News & Observer
GSK sees rise in sales of vaccines, healthcare productsAdvair asthma treatment. GSK is struggling to develop blockbuster drugs as old
GSK sees rise in sales of vaccines, healthcare products
The News & Observer / Posted 5 days ago
Advair asthma treatment. GSK is struggling to develop blockbuster drugs as older treatments lose patent protection. CEO Andrew Witty says the results demonstrate momentum, "driven by growth in sales of our new products, effective cost control... Read more
5 related stories
5d
Belfast Telegraph
GlaxoSmithKline bolsters profits by nearly a fiftha series of asset swaps with Swiss rival Novartis. The company is also on the
GlaxoSmithKline bolsters profits by nearly a fifth
Belfast Telegraph / Posted 5 days ago
a series of asset swaps with Swiss rival Novartis. The company is also on the hunt for a new chief executive after Sir Andrew Witty announced he will retire on March 31 2017, ending more than three decades with the business. He said the first... Read more
5d
Your Hometown Lima Stations
GSK sees rise in sales of vaccines, healthcare productsAdvair asthma treatment. GSK is struggling to develop blockbuster drugs as old
GSK sees rise in sales of vaccines, healthcare products
Your Hometown Lima Stations / Posted 5 days ago
Advair asthma treatment. GSK is struggling to develop blockbuster drugs as older treatments lose patent protection. CEO Andrew Witty says the results demonstrate momentum, "driven by growth in sales of our new products, effective cost control... Read more
5 related stories
5d
Salon.com
GSK sees rise in sales of vaccines, healthcare productsAdvair asthma treatment. GSK is struggling to develop blockbuster drugs as old
GSK sees rise in sales of vaccines, healthcare products
Salon.com / Posted 5 days ago
Advair asthma treatment. GSK is struggling to develop blockbuster drugs as older treatments lose patent protection. CEO Andrew Witty says the results demonstrate momentum, “driven by growth in sales of our new products, effective cost control... Read more
5 related stories
5d
Island Packet
GSK sees rise in sales of vaccines, healthcare productsAdvair asthma treatment. GSK is struggling to develop blockbuster drugs as old
GSK sees rise in sales of vaccines, healthcare products
Island Packet / Posted 5 days ago
Advair asthma treatment. GSK is struggling to develop blockbuster drugs as older treatments lose patent protection. CEO Andrew Witty says the results demonstrate momentum, "driven by growth in sales of our new products, effective cost control... Read more
5 related stories
5d
Daily Herald
GSK sees rise in sales of vaccines, healthcare productsAdvair asthma treatment. GSK is struggling to develop blockbuster drugs as old
GSK sees rise in sales of vaccines, healthcare products
Daily Herald / Posted 5 days ago
Advair asthma treatment. GSK is struggling to develop blockbuster drugs as older treatments lose patent protection. CEO Andrew Witty says the results demonstrate momentum, "driven by growth in sales of our new products, effective cost control... Read more
5 related stories
5d
ABC News
GSK Sees Rise in Sales of Vaccines, Healthcare ProductsAdvair asthma treatment. GSK is struggling to develop blockbuster drugs as old
GSK Sees Rise in Sales of Vaccines, Healthcare Products
ABC News / Posted 5 days ago
Advair asthma treatment. GSK is struggling to develop blockbuster drugs as older treatments lose patent protection. CEO Andrew Witty says the results demonstrate momentum, "driven by growth in sales of our new products, effective cost control... Read more
5 related stories
5d
Herald Sun
Better margins new drugs keep GSK on trackto achieve a promised return to growth in 2016. The British drugmaker, which i
Better margins new drugs keep GSK on track
Herald Sun / Posted 5 days ago
to achieve a promised return to growth in 2016. The British drugmaker, which is seeking a new chief executive to replace Andrew Witty in 2017, said on Wednesday that demand for recently launched respiratory and HIV medicines had offset falling... Read more
6 related stories
5d
Weekly Times
Better margins new drugs keep GSK on trackto achieve a promised return to growth in 2016. The British drugmaker, which i
Better margins new drugs keep GSK on track
Weekly Times / Posted 5 days ago
to achieve a promised return to growth in 2016. The British drugmaker, which is seeking a new chief executive to replace Andrew Witty in 2017, said on Wednesday that demand for recently launched respiratory and HIV medicines had offset falling... Read more
6 related stories
5d
Perth Now
Better margins new drugs keep GSK on trackto achieve a promised return to growth in 2016. The British drugmaker, which i
Better margins new drugs keep GSK on track
Perth Now / Posted 5 days ago
to achieve a promised return to growth in 2016. The British drugmaker, which is seeking a new chief executive to replace Andrew Witty in 2017, said on Wednesday that demand for recently launched respiratory and HIV medicines had offset falling... Read more
6 related stories
5d
The Courier Mail
Better margins new drugs keep GSK on trackto achieve a promised return to growth in 2016. The British drugmaker, which i
Better margins new drugs keep GSK on track
The Courier Mail / Posted 5 days ago
to achieve a promised return to growth in 2016. The British drugmaker, which is seeking a new chief executive to replace Andrew Witty in 2017, said on Wednesday that demand for recently launched respiratory and HIV medicines had offset falling... Read more
6 related stories
5d
Channel NewsAsia
Better margins and new drugs keep GlaxoSmithKline on trackto achieve a promised return to growth in 2016. The British drugmaker, which i
Better margins and new drugs keep GlaxoSmithKline on track
Channel NewsAsia / Posted 5 days ago
to achieve a promised return to growth in 2016. The British drugmaker, which is seeking a new chief executive to replace Andrew Witty in 2017, said on Wednesday that demand for recently launched respiratory and HIV medicines had offset falling... Read more
6 related stories
13d
TheStreet.com
Skip GlaxoSmithKline, but buy Johnson & Johnsonis 29 cents in earnings per share on revenue of $8.45 billion. Last month, Gla
Skip GlaxoSmithKline, but buy Johnson & Johnson
TheStreet.com / Posted 13 days ago
is 29 cents in earnings per share on revenue of $8.45 billion. Last month, GlaxoSmithKline announced its chief executive, Andrew Witty, would retire in March 2017. Witty, a 31-year veteran of the drugmaker, led the company through a series of... Read more
1m
MedCity News
Will GSK's IP strategy change reduce drug prices in low-income countries?pharma companies that they’ll be sued over patent infringement in these countri
Will GSK's IP strategy change reduce drug prices in low-income countries?
MedCity News / Posted a month ago
pharma companies that they’ll be sued over patent infringement in these countries and improve access to drugs. GSK CEO Sir Andrew Witty said, the changes by the company are intended to make it as clear and simple as possible for generic... Read more
m
dna
GSK to adopt graduated approach to patent drugs; aims to make drugs affordablein the world's poorest states, leaving the way clear for generic companies to m
GSK to adopt graduated approach to patent drugs; aims to make drugs affordable
dna / Posted 1 months ago
in the world's poorest states, leaving the way clear for generic companies to make cheap copies, GSK's Chief Executive Andrew Witty said. For lower middle-income countries, GSK will seek patents but it aims to strike licence deals that allow... Read more
11 related stories
m
express
Business news: TUI, Royal London, GlaxoSmithKline, Booker Groupwill offer licences for 10 years in return for a small royalty. The measures co
Business news: TUI, Royal London, GlaxoSmithKline, Booker Group
express / Posted 1 months ago
will offer licences for 10 years in return for a small royalty. The measures cover about 85 countries. Glaxo chief Sir Andrew Witty said: “The changes aim to make it as simple as possible for generic manufacturers to make and supply versions of... Read more
m
CNBC
GSK promises reduced drug patentsthat many new drugs are simply too expensive for billions of people in Africa,
GSK promises reduced drug patents
CNBC / Posted 1 months ago
that many new drugs are simply too expensive for billions of people in Africa, Asia and Latin America. GSK Chief Executive Andrew Witty has long been a proponent of improving drug access and the initiative may consolidate his reputation in the... Read more
11 related stories
m
Market Watch
Glaxo drops drug patents in low-income countriesmedicines for these markets owing to the risk of being sued by pharmaceutical c
Glaxo drops drug patents in low-income countries
Market Watch / Posted 1 months ago
medicines for these markets owing to the risk of being sued by pharmaceutical companies, according to Glaxo Chief Executive Andrew Witty. "By doing this we're taking away one potential issue or excuse...which is that generic companies hold back... Read more
11 related stories
m
Fortune
GlaxoSmithKline Is Expanding Drug Access to the World's Poorest Countriesunder the global Medicines Patent Pool. “In itself, IP is not a barrier to acc
GlaxoSmithKline Is Expanding Drug Access to the World's Poorest Countries
Fortune / Posted 1 months ago
under the global Medicines Patent Pool. “In itself, IP is not a barrier to access to medicines,” said outgoing GSK CEO Sir Andrew Witty in a statement. “However, we recognize that the global healthcare challenge requires us to be flexible in our... Read more
11 related stories
m
The Economic Times
GlaxoSmithKline promises reduced drug patents to help world's poorthat many new drugs are simply too expensive for billions of people in Africa,
GlaxoSmithKline promises reduced drug patents to help world's poor
The Economic Times / Posted 1 months ago
that many new drugs are simply too expensive for billions of people in Africa, Asia and Latin America. GSK Chief Executive Andrew Witty has long been a proponent of improving drug access and the initiative may consolidate his reputation in the... Read more
11 related stories
m
iol.co.za
GSK to patent to help the poorits drugs in the world's poorest states, leaving the way clear for generic comp
GSK to patent to help the poor
iol.co.za / Posted 1 months ago
its drugs in the world's poorest states, leaving the way clear for generic companies to make cheap copies, Chief Executive Andrew Witty said. For lower middle income countries, GSK will seek patents but it aims to strike licence deals that allow... Read more
11 related stories
m
Perth Now
Poor countries helped by GSK patent planits drugs in the world's poorest states, leaving the way clear for generic comp
Poor countries helped by GSK patent plan
Perth Now / Posted 1 months ago
its drugs in the world's poorest states, leaving the way clear for generic companies to make cheap copies, Chief Executive Andrew Witty said on Thursday. For lower middle income countries, GSK will seek patents but it aims to strike licence deals... Read more
11 related stories
m
Adelaide Now
Poor countries helped by GSK patent planits drugs in the world's poorest states, leaving the way clear for generic comp
Poor countries helped by GSK patent plan
Adelaide Now / Posted 1 months ago
its drugs in the world's poorest states, leaving the way clear for generic companies to make cheap copies, Chief Executive Andrew Witty said on Thursday. For lower middle income countries, GSK will seek patents but it aims to strike licence deals... Read more
11 related stories
m
Herald Sun
Poor countries helped by GSK patent planits drugs in the world's poorest states, leaving the way clear for generic comp
Poor countries helped by GSK patent plan
Herald Sun / Posted 1 months ago
its drugs in the world's poorest states, leaving the way clear for generic companies to make cheap copies, Chief Executive Andrew Witty said on Thursday. For lower middle income countries, GSK will seek patents but it aims to strike licence deals... Read more
11 related stories
m
Weekly Times
Poor countries helped by GSK patent planits drugs in the world's poorest states, leaving the way clear for generic comp
Poor countries helped by GSK patent plan
Weekly Times / Posted 1 months ago
its drugs in the world's poorest states, leaving the way clear for generic companies to make cheap copies, Chief Executive Andrew Witty said on Thursday. For lower middle income countries, GSK will seek patents but it aims to strike licence deals... Read more
11 related stories
m
The Courier Mail
Poor countries helped by GSK patent planits drugs in the world's poorest states, leaving the way clear for generic comp
Poor countries helped by GSK patent plan
The Courier Mail / Posted 1 months ago
its drugs in the world's poorest states, leaving the way clear for generic companies to make cheap copies, Chief Executive Andrew Witty said on Thursday. For lower middle income countries, GSK will seek patents but it aims to strike licence deals... Read more
11 related stories
More

People in this news